MX2018004286A - Metodos de tratamiento de lesiones o condiciones relacionadas con el edema del sistema nervioso central. - Google Patents

Metodos de tratamiento de lesiones o condiciones relacionadas con el edema del sistema nervioso central.

Info

Publication number
MX2018004286A
MX2018004286A MX2018004286A MX2018004286A MX2018004286A MX 2018004286 A MX2018004286 A MX 2018004286A MX 2018004286 A MX2018004286 A MX 2018004286A MX 2018004286 A MX2018004286 A MX 2018004286A MX 2018004286 A MX2018004286 A MX 2018004286A
Authority
MX
Mexico
Prior art keywords
reducing
conditions related
treating
cns edema
conditions
Prior art date
Application number
MX2018004286A
Other languages
English (en)
Inventor
Martin Jacobson Sven
Original Assignee
Biogen Chesapeake Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Chesapeake Llc filed Critical Biogen Chesapeake Llc
Publication of MX2018004286A publication Critical patent/MX2018004286A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente tecnología está relacionada con la reducción o el tratamiento del hinchamiento neurológico y condiciones relacionadas con los inhibidores de los canales de SUR1-TRPM4; en algunas modalidades, los métodos incluyen: reducir el deterioro neurológico tardío o prevenir la muerte, reducir el desplazamiento de la línea media cerebral, reducir el grado de discapacidad en un sujeto, contrarrestar los niveles de glucosa en sangre en un sujeto que recibe un inhibidor de los canales de SUR1-TRPM4, prevenir el edema cerebral, monitorear la actividad de las enzimas del hígado junto con el tratamiento de las lesiones o condiciones relacionadas con el edema del SNC, o monitorear la actividad cardiaca junto con el tratamiento de las lesiones o condiciones relacionadas con el edema del SNC.
MX2018004286A 2015-10-07 2016-10-07 Metodos de tratamiento de lesiones o condiciones relacionadas con el edema del sistema nervioso central. MX2018004286A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562238461P 2015-10-07 2015-10-07
PCT/US2016/055988 WO2017062765A1 (en) 2015-10-07 2016-10-07 Methods of treating injuries or conditions related to cns edema

Publications (1)

Publication Number Publication Date
MX2018004286A true MX2018004286A (es) 2018-08-09

Family

ID=58488580

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004286A MX2018004286A (es) 2015-10-07 2016-10-07 Metodos de tratamiento de lesiones o condiciones relacionadas con el edema del sistema nervioso central.

Country Status (15)

Country Link
US (2) US20180280325A1 (es)
EP (1) EP3359162B1 (es)
JP (3) JP7349786B2 (es)
KR (1) KR20180063296A (es)
CN (2) CN115737816A (es)
AU (2) AU2016335767B2 (es)
BR (1) BR112018006925A2 (es)
CA (1) CA3001321A1 (es)
EA (1) EA201890893A1 (es)
ES (1) ES2940669T3 (es)
HK (1) HK1257542A1 (es)
IL (1) IL258509B2 (es)
MA (1) MA45574A (es)
MX (1) MX2018004286A (es)
WO (1) WO2017062765A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109512805B (zh) 2012-05-08 2021-12-31 埃罗米克斯公司 用于治疗水通道蛋白介导的疾病的化合物
JP6535338B2 (ja) 2013-11-06 2019-06-26 エアロミクス・インコーポレイテッドＡｅｒｏｍｉｃｓ，Ｉｎｃ． 新規製剤
WO2020041905A1 (en) * 2018-08-31 2020-03-05 The University Of British Columbia Methods for identifying compounds suitable for treatment of central nervous system trauma and uses of those compounds
CN113874002A (zh) * 2019-05-02 2021-12-31 生物切萨皮克有限责任公司 治疗患有中枢神经系统挫伤的受试者的方法
WO2022012666A1 (zh) * 2020-07-17 2022-01-20 上海森辉医药有限公司 磺酰脲类衍生物及其医药用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856360A (en) 1996-05-03 1999-01-05 Children's Hospital Medical Center Pharmaceutical method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock
HUE051368T2 (hu) 2002-03-20 2021-03-01 Univ Maryland Nem szelektív kationcsatorna idegsejtekben és a csatornát blokkoló vegyületek az agyduzzanat kezelésére
US8980952B2 (en) * 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
US20050246000A1 (en) * 2004-05-03 2005-11-03 Seacoast Technologies, Inc. Cooled craniectomy
WO2009002832A2 (en) 2007-06-22 2008-12-31 University Of Maryland, Baltimore Inhibitors of ncca-atp channels for therapy
PT2868315T (pt) * 2007-12-04 2017-09-04 Remedy Pharmaceuticals Inc Formulações melhoradas e métodos para liofilização e liofilizados assim produzidos
CA3225438A1 (en) 2010-07-19 2012-01-26 Remedy Pharmaceuticals, Inc. Methods of intravenous adminstration of glyburide and other drugs

Also Published As

Publication number Publication date
BR112018006925A2 (pt) 2018-10-16
AU2022279369A1 (en) 2023-01-19
JP2018530564A (ja) 2018-10-18
EA201890893A1 (ru) 2018-09-28
CN115737816A (zh) 2023-03-07
JP7349786B2 (ja) 2023-09-25
CA3001321A1 (en) 2017-04-13
ES2940669T3 (es) 2023-05-10
JP2023053274A (ja) 2023-04-12
US11951085B2 (en) 2024-04-09
AU2016335767A8 (en) 2018-06-28
CN108348534A (zh) 2018-07-31
KR20180063296A (ko) 2018-06-11
EP3359162A1 (en) 2018-08-15
HK1257542A1 (zh) 2019-10-25
WO2017062765A1 (en) 2017-04-13
EP3359162A4 (en) 2019-08-28
IL258509B (en) 2022-12-01
MA45574A (fr) 2019-05-15
AU2016335767B2 (en) 2022-10-06
AU2016335767A1 (en) 2018-05-24
JP2021073317A (ja) 2021-05-13
IL258509A (en) 2018-05-31
EP3359162B1 (en) 2022-12-21
US20220125750A1 (en) 2022-04-28
US20180280325A1 (en) 2018-10-04
IL258509B2 (en) 2023-04-01

Similar Documents

Publication Publication Date Title
MX2018004286A (es) Metodos de tratamiento de lesiones o condiciones relacionadas con el edema del sistema nervioso central.
PH12019502254A1 (en) Methods and systems for modulating stimuli to the brain with biosensors
EA201890059A1 (ru) Ингибиторы hpk1 и способы их применения
MX2023001527A (es) Compuestos con actividad inductora de ferroptosis y metodos de uso de estos.
PH12020500352A1 (en) Therapeutic uses of empagliflozin
MX2021013146A (es) Inhibidores de receptores del factor de crecimiento de fibroblastos (fgfr) y metodos de uso de los mismos.
MX2016005159A (es) Metodos de diagnostico y tratamiento de trastornos eosinofilicos.
PH12015502610A1 (en) Compounds for kinase modulation, and indications therefor
MX366204B (es) Pronostico medico y prediccion de la respuesta al tratamiento utilizando multiples actividades de la trayectoria de señalizacion celular.
MX2016017288A (es) Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer.
MX2017007976A (es) Compuestos inhibidores de parg.
PH12015500114B1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
CR20220325A (es) Fluoroalquil-oxadiazoles y sus usos
MX2020005567A (es) Metodos de tratamiento con asparaginasa.
MX2012000034A (es) Metodos para el tratamiento o la prevencion de la fatiga.
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
MX2020013740A (es) Uso de empagliflozina para el tratamiento de trastornos metabolicos, la prevencion, y para la reduccion del riesgo de sufrir o para retrasar la ocurrencia de un episodio cardiovascular.
NZ628054A (en) Treatment of addiction and impulse-control disorders using pde7 inhibitors
SG10202010306RA (en) Systems, devices, and methods for self-contained personal monitoring of behavior to improve mental health and other behaviorally-related health conditions
MX2021010173A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso.
MX362806B (es) Inhibidores biciclicos.
MX2022000845A (es) Compuestos inhibidores.
GB201202561D0 (en) Treatment of skin disorders
EA201991650A1 (ru) Способы лечения неврологических расстройств
MX2017014782A (es) Metodo para el tratamiento de enfermedad neurologica.